Table 3.
Subgroup Analysis of TXA and placebo
| Mortality | Adverse Events | Neurosurgical Intervention | Rebleeding | Mean hemorrhage volume | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| RR, 95% |
P-Value | RR, 95% |
P-Value | RR, 95% |
P-Value | RR, 95% |
P-Value | RR, 95% |
P-Value | |
| Study design | ||||||||||
| Multisite RCT |
0.99 [0.79–1.24] |
0.90 |
0.91 [0.73–1.13] |
0.38 |
1.01 [0.61–1.55] |
0.96 |
0.81 [0.59–1.10] |
0.17 |
-0.08 [-0.32, 0.16] |
0.52 |
| Single site RCT |
1.03 [0.73–1.43] |
0.88 |
1.07 [0.39–2.88] |
0.90 |
1.15 [0.89–1.48] |
0.29 |
1.65 [0.94–2.89] |
0.88 |
-0.46 [-0.72, -0.20] |
0.0005 |
| Enrollment time after trauma | ||||||||||
| < 3 h |
0.94 [0.87–1.02] |
0.15 |
0.91 [0.77–1.08] |
0.28 |
1.18 [0.89–1.55] |
0.24 |
0.91 [0.75–1.10] |
0.34 |
-0.50 [-0.94, -0.05] |
0.03 |
| > 3 h |
0.76 [0.51–1.11] |
0.15 |
2.45 [0.92–6.52] |
0.07 |
1.00 [0.70–1.44] |
0.99 |
1.14 [0.65–2.02] |
0.64 |
-0.33 [-0.65, 0.00] |
0.05 |
| TXA dose | ||||||||||
| 2 g TXA bolus followed by a placebo infusion |
0.80 [0.56–1.15] |
0.22 |
1.22 [0.85–1.74] |
0.28 | N/A | N/A |
1.24 [0.91–1.70] |
0.17 | N/A | N/A |
| 1 g TXA bolus followed by 1 g TXA maintenance |
1.01 [0.82–1.24] |
0.95 |
1.00 [0.92–1.08] |
0.97 | N/A | N/A |
1.00 [0.71–1.41] |
1 | N/A | N/A |
N/A Not applicable